ClinicalTrials.gg
RecruitingNCT06017778Updated Aug 30, 2023

Impact Of Whole Body Vibration on Planter /Dorsi Flexor Ratio, Pain and Functional Activities in Patellofemoral Pain Syndrome

An interventional study of whole body vibration and traditional exercise group in Patellofemoral Pain Syndrome, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2023-08-30.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2023, 3 years ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Patellofemoral Pain Syndrome by Cairo University — 12 open to participants now, 13 under way, none of them phase 3. Patellofemoral Pain Syndrome · Cairo University.

Planned enrollment
5th of 22
60 · median 58
Started
2023
with 5 others
No phase
22 of 30
10 open now
Primary completion
2023-10
later than 0 of 12 live
Registered
12th of 30
by date

Among the 30 studies in Patellofemoral Pain Syndrome by Cairo University, this one is the 5th largest by planned enrollment of the 22 interventional ones that give a count, is one of 6 that started in 2023, is one of 22 with no phase, reaches primary completion later than 0 of the 12 other live ones, and was the 12th registered.

Patellofemoral Pain Syndrome

297 studies on the registry are indexed under Patellofemoral Pain Syndrome; 73 are open to participants now.

Browse Patellofemoral Pain Syndrome studies →

Open to participants now

12 of the 30 studies in Patellofemoral Pain Syndrome by Cairo University are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 44 Patellofemoral Pain Syndrome studies recruiting now, 3 (7%) set no upper age limit and 40 (91%) stop at 75 or younger; 6 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Patellofemoral Pain Syndrome by Cairo University, or all of them as a file.
02

Study summary

Patellofemoral pain syndrome (PFPS) can significantly affect an individual's ability perform to functional activities, such as walking, running, climbing stairs, and sitting for prolonged periods.

PFPS is often associated with pain and discomfort in the front of the knee, which can limit an individual's range of motion and cause difficulty with weight-bearing activities. The pain may also be exacerbated by activities that involve bending the knee, such as squatting or kneeling.

Whole body vibration (WBV) has been suggested as a potential intervention for patellofemoral pain syndrome (PFPS). Some studies have shown that WBV can improve muscle strength, balance, and proprioception, which are all factors that may contribute to PFPS. Additionally, WBV may help reduce pain and improve functional abilities in individuals with PFPS However, the evidence for the effectiveness of WBV as an intervention for PFPS is still limited, and more research is needed to fully understand its potential benefits and limitations. It is important to note that WBV may not be suitable for all individuals with PFPS.

Read the detailed description

Patellofemoral pain syndrome (PFPS) can significantly affect an individual's ability perform to functional activities, such as walking, running, climbing stairs, and sitting for prolonged periods.

PFPS is often associated with pain and discomfort in the front of the knee, which can limit an individual's range of motion and cause difficulty with weight-bearing activities. The pain may also be exacerbated by activities that involve bending the knee, such as squatting or kneeling.

Whole body vibration (WBV) has been suggested as a potential intervention for patellofemoral pain syndrome (PFPS). Some studies have shown that WBV can improve muscle strength, balance, and proprioception, which are all factors that may contribute to PFPS. Additionally, WBV may help reduce pain and improve functional abilities in individuals with PFPS.

However, the evidence for the effectiveness of WBV as an intervention for PFPS is still limited, and more research is needed to fully understand its potential benefits and limitations. It is important to note that WBV may not be suitable for all individuals with PFPS.

HYPOTHESES:

There will be no significant difference on dorsi/planter flexor ratio , functional activities and pain level after adding the whole body vibration to traditional treatment of PFPS

RESEARCH QUESTION:

What is the impact of whole-body vibration on dorsi/planter flexor ratio, functional activities and pain levels in individuals with PFPS?

03

Conditions studied

  • Patellofemoral Pain Syndrome

Keywords

  • Patellofemoral pain syndrome
  • vibration
  • Planter/Dorsi ratio
  • pain
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: Adults aged 18 -35 years
  2. Symptoms: Pain in the anterior or retro patellar knee region during activities such as running, jumping, squatting, or prolonged sitting
  3. Duration: Pain lasting at least 6 weeks

Exclusion criteria

Exclusion Criteria:

  1. Presence of other knee conditions: Individuals with PFPS who also have other knee conditions such as ligament or meniscal injuries, osteoarthritis, or patellar tendinopathy may be excluded.
  2. History of knee surgery: Patients who have undergone any knee surgery may be excluded as this may affect the outcomes of the study.
  3. Systemic conditions: Patients with systemic conditions that may affect the musculoskeletal system such as rheumatoid arthritis or lupus may be excluded.
  4. Pregnancy: Pregnant women with PFPS may be excluded as pregnancy may affect the outcomes of the study.
  5. Inability to comply with study requirements: Patients who are unable to comply with the study requirements such as attending follow-up appointments or completing questionnaires may be excluded.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    whole body viberation group

    Device: whole body vibration · Other: traditional exercise group

  • Active comparator
    control group

    Other: traditional exercise group

Interventions

  • Devicewhole body vibration

    patients will receive WBV training in addition to traditional training will be performed on a tri-planar (mostly vertical, Z axis) oscillating vibration platform (Power PlateR pro5™; Power Plate North America, Inc., Northbrook, IL,USA) for 20-30 minutes per session. WBV training will be supervised and performed in a clinic three days a week with at least one day between each session for four weeks (total of 12 sessions).

  • Othertraditional exercise group

    10 minutes warm-up (lower extremity stretching exercises), 20-30 minutes period of strength exercises with three sets of 10-15 repetitions (isometric quadriceps setting, knee extensions, double-legged wall squat), and 5 minutes cool-down (lower extremity stretching exercises). Lower extremity stretching exercises consisted of quadriceps, hamstring, gastrocnemius and iliotibial band stretching with 3 repetitions for 30 s each muscle.

06

What researchers measure

Primary outcomes

  1. Dorsi/planter torque ratio

    dorsi/planter torque ratio will be measured through the Biodex System 4-Pro Isokinetic Strength Dynamometer for assessment of muscle torque

    Time frame: one month

  2. functional activities

    Kujala Anterior Knee Pain Scale, which includes questions related to functional activities.

    Time frame: one month

  3. Pain intensity

    10 cm Visual Analogue Scale (VAS) was used to assess pain intensity during activity in patients with patellofemoral pain (PFP). The scale ranged from 0, indicating "no pain," to 100, representing the "worst pain imaginable.

    Time frame: one month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Informed consent form

Time frame: 6 months after publication

Access criteria: study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2023; primary completion for Oct 2023, 2 months later.

Of 153 non-industry interventional studies with no phase under Patellofemoral Pain Syndrome, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 21. This study's planned 2 months is below that.

Counting every sponsor, half of 157 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2023
First posted
Aug 30, 2023
StartEst.
Aug 30, 2023
Primary completionEst.
Oct 30, 2023
CompletionEst.
Nov 30, 2023
Last update
Aug 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06017778
Lead sponsor
Cairo University
Responsible party
Radwa T. Elshorbagy (assistant professor, Cairo University) — Principal investigator
First posted
Aug 30, 2023
Start date
Aug 30, 2023 (estimated)
Primary completion
Oct 30, 2023 (estimated)
Completion
Nov 30, 2023 (estimated)
Last update
Aug 30, 2023

Study contacts

Radwa Elshorbagy
Contact
Rtelshorbagy@ju.edu.sa
00966500920691

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion